However, the two CMF armoured brigade headquarters were disbanded.
The two CMF armoured brigade headquarters were also disbanded.
The European Organization for Research and Treatment of Cancer studied two CMF (cyclophosphamide, methotrexate, and 5-fluorouracil) regimens [ 43]: a classic 28-day regimen incorporating daily oral cyclophosphamide for 14 days and a modified intravenous schedule with bolus cyclophosphamide every 3 weeks.
This paper documents the construction and instrumentation of three CMF systems on the Musselwhite mine located in Ontario, Canada and presents results of 3-year real time monitoring.
Adjuvant therapy consisted of tamoxifen in 53 cases, toremifene in 14, other hormonal therapy in three, CMF (cyclophosphamide, methotrexate, fluorouracil) in 56, and CEF (cyclophosphamide, epirubicin, fluorouracil) of CAF (cyclophosphamide, doxorubicin, fluorouracil) in five; in six cases the type of systemic adjuvant therapy given was not available.
The trial has both proved an advantage for the Bonadonna block-scheduling anthracycline approach [ 8], and improved outcomes for breast cancer patients in the UK by insisting on adherence to the two classical CMF schedules (oral or intravenous cyclophosphamide).
However, in the ER-negative cohort, three cycles CMF provided 3 months more of Q-TWiST than Tam alone, while for the larger ER-positive cohort, CMF provided no benefit.
Owing to its inherent design, with an imbalanced number of chemotherapy cycles between arms (six for CMF and 10 for ACMF), our trial cannot clarify whether the observed DFS improvement is related to the introduction of the anthracycline or to the longer chemotherapy administration in the sequential arms.
This study randomized patients to four cycles of FEC, followed by four cycles of docetaxel or a control arm of the physicians' choice: either four cycles of epirubicin followed by four cycles of CMF, or eight cycles of CMF.
Women aged 65 or older with invasive T1 T4 breast cancer (ER positive or negative) and node positive or negative, were randomised to receive standard chemotherapy (six cycles of CMF or four cycles of AC, according to physician choice), or six cycles of oral capecitabine.
The HE10/00 trial [ 31, 32] was a randomized phase III trial (ACTRN12609001036202) in which patients were treated with E-T-CMF (exactly as in the HE10/97 trial) or with four cycles of epirubicin/paclitaxel (ET) combination (given on the same day) every three weeks followed by three cycles of intensified CMF every two weeks (ET-CMF).
